Drugs / IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells
IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04003649 | Dec 2019 → Dec 2024 overdue | glioblastoma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04003649 ↗ |
| Action | Deplete | “may attack specific glioma cells and stop them from growing or kill them.” NCT04003649 ↗ |
| Modality | Cell therapy | “Biological therapies, such as IL13Ralpha2-CAR T cells, use substances made from living organisms” NCT04003649 ↗ |
| Route | Other | “Given ITV/ITC” NCT04003649 ↗ |